September 9, 2013- Interviewed by Steven E. Greer, MD
Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University of Miami, and Chairman of the NIH’s TrialNet, discusses the “prandial problem” that requires “super rapid acting” insulin, and some new insulins in clinical trials, including inhaled Afrezza.
Disclosure: Jay Skyler, MD, has disclosed the following relevant financial relationships:
Served as an advisor/consultant for: Sanofi-Aventis; Gilead Sciences, Inc., Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.; Cebix, Incorporated; Lilly USA, LLC, Dr. Skyler is an unpaid member of the scientific advisory board of MannKind
Received grants for clinical research from: Halozyme Therapeutics; Intuity Medical, Inc.; Mesoblast Limited; Osiris Therapeutics, Inc.
Owns stocks, stock options, or bonds from: Dexcom, Inc.; Amylin Pharmaceuticals, Inc.; Moerae Matrix; Opko Health Inc.; Patton Medical Devices, LP